IN THE NEWS

Inhalation

23December2025

Ritedose 2025 Year-In-Review

Ritedose’s 2025 Year-In-Review highlights a year of growth, innovation, and purpose-driven impact, advancing patient access through expanded generics, operational excellence, and community investment.

Automated pharmaceutical warehouse with a yellow robotic arm stacking cardboard boxes, illustrating Ritedose’s focus on transparency, efficiency, and solutions for drug shortages.

29October2025

Ritedose Now Offers the Largest Nebulized Drug Portfolio in the U.S.: FDA Approves the Company to Manufacture Generic Tobramycin Inhalation Solution

The Ritedose Corporation (Ritedose) announced that the U.S. Food and Drug Administration (FDA) approved its manufacturing and distribution of Tobramycin Inhalation Solution to treat patients six years and older with infections of Pseudomonas aeruginosa, a common bacterial infection among cystic…

16September2024

Ritedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)*

September 17, 2024 — The Ritedose Corporation, Inc. (Ritedose), the largest CDMO in the United States specializing in sterile Blow Fill Seal (BFS) production of unit dose solutions for the ophthalmic and respiratory markets, is proud to partner with Verona…

11July2024

Ritedose, the Leading Pharmaceutical Manufacturer (CDMO) Specializing in Sterile Blow-Fill-Seal, Expands its BFS Capacity to Meet the Growing Demand for Ophthalmic and Respiratory Medications

COLUMBIA, S.C. June 20, 2024 – The Ritedose Corporation (Ritedose), the leading contract development and manufacturing organization (CDMO) specializing in sterile Blow Fill Seal (BFS) production, announces a significant expansion of its production capabilities to meet the demand for ophthalmic…

24August2023

Ritedose Pharmaceuticals Launches Cromolyn Sodium Inhalation Solution, USP (20 mg/2 ml)

COLUMBIA, S.C. (August 24, 2023) – Ritedose, a pharmaceutical manufacturer located in South Carolina, launched a new sterile unit dose generic product, Cromolyn Sodium Inhalation Solution, USP (20 mg/2 ml). The single-dose vial product joins a range of other inhalation…

13April2023

Ritedose Pharmaceuticals Launches New Product: Arformoterol Tartrate Inhalation Solution (15 mcg/2 ml)

COLUMBIA, S.C. (April 13, 2023) – Ritedose, a pharmaceutical manufacturer located in South Carolina, just launched a new single unit dose oral inhalation product, Arformoterol Tartrate (15 mcg/2 ml), making the company the largest generic drug maker of its kind.…

11October2022

Ritedose Reaches Milestone with Asset Purchase

COLUMBIA, S.C.—The Ritedose Corporation, LLC now offers the most complete nebulized inhalation drug portfolio in the industry with the purchase of the Arformoterol Tartrate asset from PAI Pharma of Greenville, S.C. (more…)